Opus Genetics (IRD) Gains from Investment Securities (2011 - 2025)
Opus Genetics (IRD) reported Gains from Investment Securities of $100000.0 for Q3 2025, down 83.11% year-over-year from $592222.0 in Q3 2024, and down 99.55% quarter-over-quarter from $22.2 million in Q2 2025.
Opus Genetics (IRD) Gains from Investment Securities (2011 - 2025) Analysis & Trends
Opus Genetics (IRD) has 15 years of Gains from Investment Securities data on file, last reported at $100000.0 in Q3 2025.
- Gains from Investment Securities for Q3 2025 came in at $100000.0, down 83.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $100000.0 (up 284.62% YoY), and the FY2025 annual result was $22.2 million, up 1526.23% from the prior year.
- Gains from Investment Securities declined to $100000.0 in Q3 2025 per IRD's latest filing, from $22.2 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $22.2 million in Q2 2025 and troughed at $26000.0 in Q4 2023.
- A 5-year average of $2.0 million and a median of $259086.0 in 2024 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 8479.82% in 2025 and fell as far as 83.11% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $128000.0 in 2021, then surged by 30.47% to $167000.0 in 2022, then tumbled by 84.43% to $26000.0 in 2023, then jumped by 2177.78% to $592222.0 in 2024, then slumped by 83.11% to $100000.0 in 2025.
- Business Quant data shows IRD's Gains from Investment Securities at $100000.0 in Q3 2025, $22.2 million in Q2 2025, and $592222.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Opus Genetics | 355.39 Mn | 295.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 22.23 Mn |
| Jun 30, 2025 | 22.23 Mn |
| Sep 30, 2024 | 592,222.00 |
| Sep 30, 2024 | 592,222.00 |
| Jun 30, 2024 | 259,086.00 |
| Jun 30, 2024 | 259,086.00 |
| Dec 31, 2023 | 26,000.00 |
| Dec 31, 2023 | 26,000.00 |
| Sep 30, 2023 | 793,578.00 |
| Sep 30, 2023 | 793,578.00 |
| Jun 30, 2023 | 124,880.00 |
| Jun 30, 2023 | 124,880.00 |
| Mar 31, 2023 | 291,584.00 |
| Mar 31, 2023 | 291,584.00 |
| Sep 30, 2022 | 167,000.00 |
| Sep 30, 2022 | 167,000.00 |
| Mar 31, 2022 | 552,305.00 |
| Mar 31, 2022 | 552,305.00 |